Methods The rat model of ulcerative colitis was developed with 2, 4-dinitrochlorobenzene method. The 20th day after the end of model development, they were randomly divided into a model group, a salicylazosulfapyridine ( SASP) treatment group and an acupoint embedding thread therapy group. 方法:用2,4二硝基氯苯法造模,造模结束后,第20天将造模组随机分为模型组、柳氮磺胺吡啶(SASP)治疗组和穴位埋线治疗组。
Another group with MTX 10 mg/ week and salicylazosulfapyridine ( SASP) 2 0 g/ day, for 12 weeks. 第2组服用MTX10mg/周+柳氮磺吡啶(SASP)10g,每日2次,观察3个月。
Objective: To observe the efficacy and safety of Etiasa, a control released tablet of mesalazine, in treatment of inflammatory bowel disease ( IBD) in comparison with salicylazosulfapyridine ( SASP). 目的:观察一种新型美沙拉嗪控释剂(艾迪莎)治疗炎症性肠病(IBD)的疗效和安全性,并同水杨酸偶氮磺胺吡啶(SASP)进行比较。
Objective To explore the changes of T cell subsets in rats with experimental colitis induced by 2,4,6-trinitrobenzene sulphonic acid ( TNBS) and the effects of SASP ( Salicylazosulfapyridine) and PSL ( Prednisolone) on the experimental colitis. 目的探讨T细胞亚群在TNBS诱发大鼠实验性结肠炎模型的外周血、脾、结肠中变化特点及经柳氮磺胺吡啶(SASP)和氢化泼尼松(PSL)治疗后这些细胞的变化。
AIM: To observe the curative effect of Sanguis Draconis combined with salicylazosulfapyridine ( SASP) in the treatment of non-specific ulcerative colitis ( UC). 目的:观察血竭联合柳氮磺吡啶治疗非特异性溃疡性结肠炎(UC)的疗效。
The last 20 patients of a control group received Salicylazosulfapyridine ( SASP) 1.0, qid. The duration of treatment was four weeks in all groups. 对照组20例,口服柳氮磺吡啶(SASP)1.0qd,疗程均为4周。